tipranavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 3609 174484-41-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tipranavir
  • aptivus
  • PNU-140690
  • PNU 140690
Tipranavir is an HIV-1 protease inhibitor that inhibits the virus-specific processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19.
  • Molecular weight: 602.67
  • Formula: C31H33F3N2O5S
  • CLOGP: 7.76
  • LIPINSKI: 2
  • HAC: 7
  • HDO: 2
  • TPSA: 105.59
  • ALOGS: -6.47
  • ROTB: 11
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 23.70 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
June 22, 2005 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypomania 499.87 263.68 98 2159 6232 63480533
Jaundice cholestatic 485.61 263.68 98 2159 7226 63479539
Schizophrenia 461.33 263.68 99 2158 9853 63476912
Psychotic disorder 358.45 263.68 97 2160 25615 63461150
Hepatotoxicity 349.68 263.68 103 2154 36938 63449827
Blood bilirubin increased 327.52 263.68 98 2159 37042 63449723
Cholelithiasis 315.49 263.68 99 2158 43826 63442939

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Virologic failure 88.52 41.68 20 878 3460 34952573
Acquired immunodeficiency syndrome 83.54 41.68 14 884 504 34955529
Dyschromatopsia 58.60 41.68 10 888 401 34955632
Viral mutation identified 54.04 41.68 13 885 2941 34953092
Drug resistance 52.37 41.68 21 877 25906 34930127
Multiple-drug resistance 51.27 41.68 14 884 5225 34950808
HIV infection 46.81 41.68 10 888 1329 34954704
Viral load increased 45.59 41.68 11 887 2516 34953517

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypomania 498.74 90.75 98 2305 7446 79734539
Jaundice cholestatic 459.39 90.75 98 2305 11186 79730799
Schizophrenia 434.18 90.75 99 2304 15341 79726644
Psychotic disorder 337.28 90.75 99 2304 41303 79700682
Hepatotoxicity 333.13 90.75 103 2300 51249 79690736
Cholelithiasis 317.97 90.75 100 2303 52564 79689421
Blood bilirubin increased 295.44 90.75 100 2303 66132 79675853
Hepatic enzyme increased 209.23 90.75 104 2299 182506 79559479
Total lung capacity increased 202.06 90.75 38 2365 2260 79739725
Asthma-chronic obstructive pulmonary disease overlap syndrome 189.26 90.75 38 2365 3183 79738802
Nasal polyps 158.15 90.75 38 2365 7289 79734696
Sarcoidosis 153.28 90.75 38 2365 8297 79733688
Rhinitis allergic 138.71 90.75 38 2365 12231 79729754
Cardiac murmur 129.14 90.75 38 2365 15786 79726199
Viral mutation identified 120.36 90.75 27 2376 3831 79738154
Bronchiectasis 116.15 90.75 38 2365 22348 79719637
Condition aggravated 105.67 90.75 100 2303 501024 79240961
Vomiting 95.49 90.75 108 2295 665720 79076265

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AE09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
FDA MoA N0000000246 HIV Protease Inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
FDA EPC N0000175889 Protease Inhibitor
CHEBI has role CHEBI:35660 HIV protease inhibitors
CHEBI has role CHEBI:36044 antiviral drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Intracranial hemorrhage contraindication 1386000
Hypercholesterolemia contraindication 13644009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Hereditary factor VIII deficiency disease contraindication 28293008 DOID:12134
Hereditary factor IX deficiency disease contraindication 41788008 DOID:12259
Hepatic failure contraindication 59927004
Chronic type B viral hepatitis contraindication 61977001
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Procedure on central nervous system contraindication 118679007
Neoplasm of brain contraindication 126952004 DOID:1319
Inflammatory disease of liver contraindication 128241005
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Lesion of brain contraindication 301766008
Hypertriglyceridemia contraindication 302870006
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.13 acidic
pKa2 6.12 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Pepsin A-5 Enzyme Ki 5.70 CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
Cathepsin D Enzyme Ki 4.82 CHEMBL
Cathepsin E Enzyme Ki 5.05 CHEMBL
Pol polyprotein Enzyme INHIBITOR IC50 7.52 CHEMBL CHEMBL
CAAX prenyl protease 1 homolog Enzyme IC50 5.92 CHEMBL

External reference:

IDSource
4024917 VUID
N0000171602 NUI
D08605 KEGG_DRUG
4024917 VANDF
C0663733 UMLSCUI
CHEBI:63628 CHEBI
TPV PDB_CHEM_ID
CHEMBL222559 ChEMBL_ID
DB00932 DRUGBANK_ID
C107201 MESH_SUPPLEMENTAL_RECORD_UI
12685 IUPHAR_LIGAND_ID
7774 INN_ID
ZZT404XD09 UNII
54682461 PUBCHEM_CID
190548 RXNORM
20182 MMSL
69882 MMSL
d05538 MMSL
010844 NDDF
418721002 SNOMEDCT_US
419409009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Aptivus HUMAN PRESCRIPTION DRUG LABEL 1 0597-0002 SOLUTION 100 mg ORAL NDA 32 sections
Aptivus HUMAN PRESCRIPTION DRUG LABEL 1 0597-0002 SOLUTION 100 mg ORAL NDA 32 sections
Aptivus HUMAN PRESCRIPTION DRUG LABEL 1 0597-0003 CAPSULE, LIQUID FILLED 250 mg ORAL NDA 32 sections
Aptivus HUMAN PRESCRIPTION DRUG LABEL 1 0597-0003 CAPSULE, LIQUID FILLED 250 mg ORAL NDA 32 sections